🔗 Share this article America and Britain Secure Zero-Tariff Accord on Drugs. Conceptual image of drug exports. Britain and America have concluded a key bilateral deal that will ensure zero duties on British medicine exports going into the US market. Key Provisions of the Deal Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these vital products will be held at nothing for a duration of 36 months. This development comes after recent statements to dramatically increase duties on patented pharmaceutical products, with potential rates discussed up to double the cost. "This agreement between the Britain bolsters the global environment for cutting-edge drugs and establishes much-needed balance to American-British pharmaceutical trade," an announcement declared. Trade Impact Medicines constitute one of the UK's biggest exports to the America, which is easily the largest destination for major companies like GSK and AstraZeneca. Export figures reveal that in the year to the end of the third quarter, the UK sold medicines totaling £11.1bn to the US. This figure represented 17.4% of all goods exports in that span. "This guarantee secures employment, boosts investment and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary commented. Key NHS Changes The agreement involves several key pledges from the United Kingdom: Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%. Increased NHS Spending: There is a target to raise overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the next decade. Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be capped at 15%. Last year, refunds were more than 20%. Broader Context The pact comes amid a protracted dispute between the sector and the UK government over medicine costs and NHS adoption. This friction were exacerbated by arguments that US consumers were charged a premium for the same drugs than people in the UK and Europe. In recent months, several major drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward American operations. The Science Minister stated that the NHS must increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
Conceptual image of drug exports. Britain and America have concluded a key bilateral deal that will ensure zero duties on British medicine exports going into the US market. Key Provisions of the Deal Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these vital products will be held at nothing for a duration of 36 months. This development comes after recent statements to dramatically increase duties on patented pharmaceutical products, with potential rates discussed up to double the cost. "This agreement between the Britain bolsters the global environment for cutting-edge drugs and establishes much-needed balance to American-British pharmaceutical trade," an announcement declared. Trade Impact Medicines constitute one of the UK's biggest exports to the America, which is easily the largest destination for major companies like GSK and AstraZeneca. Export figures reveal that in the year to the end of the third quarter, the UK sold medicines totaling £11.1bn to the US. This figure represented 17.4% of all goods exports in that span. "This guarantee secures employment, boosts investment and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary commented. Key NHS Changes The agreement involves several key pledges from the United Kingdom: Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%. Increased NHS Spending: There is a target to raise overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the next decade. Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be capped at 15%. Last year, refunds were more than 20%. Broader Context The pact comes amid a protracted dispute between the sector and the UK government over medicine costs and NHS adoption. This friction were exacerbated by arguments that US consumers were charged a premium for the same drugs than people in the UK and Europe. In recent months, several major drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward American operations. The Science Minister stated that the NHS must increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.